Braftovi (encorafenib)

pCPA File Number: 21548
Negotiation Status:
Under consideration for negotiation
Indication(s):
Braftovi in combination with cetuximab, for the treatment of patients with metastatic colorectal cancer (mCRC) with a BRAF V600E mutation, as detected by a validated test, after prior therapy,
Sponsor/Manufacturer:
PFIZER CANADA ULC.
CADTH Project Number:
PC0233-000
pCPA Engagement Letter Issued:
Not Applicable
Negotiation Process Concluded:
Not Applicable